Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Identifying and characterizing hepatitis C virus hotspots in Massachusetts: a spatial epidemiological approach.

Stopka TJ, Goulart MA, Meyers DJ, Hutcheson M, Barton K, Onofrey S, Church D, Donahue A, Chui KKH.

BMC Infect Dis. 2017 Apr 20;17(1):294. doi: 10.1186/s12879-017-2400-2.

2.

Correlates of Hepatitis C Virus Infection in the Targeted Testing Program of the New York City Jail System.

Akiyama MJ, Kaba F, Rosner Z, Alper H, Kopolow A, Litwin AH, Venters H, MacDonald R.

Public Health Rep. 2017 Jan/Feb;132(1):41-47. doi: 10.1177/0033354916679367. Epub 2016 Dec 14.

PMID:
28005477
3.

The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.

Gustafson DH Sr, Landucci G, McTavish F, Kornfield R, Johnson RA, Mares ML, Westergaard RP, Quanbeck A, Alagoz E, Pe-Romashko K, Thomas C, Shah D.

Trials. 2016 Dec 12;17(1):592.

4.

Hepatitis C testing in substance use disorder treatment: the role of program managers in adoption of testing services.

Frimpong JA, D'Aunno T.

Subst Abuse Treat Prev Policy. 2016 Apr 1;11:13. doi: 10.1186/s13011-016-0057-2.

5.

Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.

Carey KJ, Huang W, Linas BP, Tsui JI.

J Subst Abuse Treat. 2016 Jul;66:54-9. doi: 10.1016/j.jsat.2016.01.009. Epub 2016 Feb 13.

6.

On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial.

Frimpong JA, D'Aunno T, Perlman DC, Strauss SM, Mallow A, Hernandez D, Schackman BR, Feaster DJ, Metsch LR.

Trials. 2016 Mar 3;17(1):117. doi: 10.1186/s13063-016-1225-4.

7.

Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections.

Fu R, Gutfraind A, Brandeau ML.

Math Biosci. 2016 Mar;273:102-13. doi: 10.1016/j.mbs.2016.01.003. Epub 2016 Jan 14.

8.

The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.

Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP.

Clin Infect Dis. 2016 Feb 1;62(3):298-304. doi: 10.1093/cid/civ894. Epub 2015 Nov 30.

9.

Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections.

Gutfraind A, Boodram B, Prachand N, Hailegiorgis A, Dahari H, Major ME.

PLoS One. 2015 Sep 30;10(9):e0137993. doi: 10.1371/journal.pone.0137993. eCollection 2015.

10.

Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.

Echevarria D, Gutfraind A, Boodram B, Major M, Del Valle S, Cotler SJ, Dahari H.

PLoS One. 2015 Aug 21;10(8):e0135901. doi: 10.1371/journal.pone.0135901. eCollection 2015.

11.

Police Encounters Among Needle Exchange Clients in Baltimore: Drug Law Enforcement as a Structural Determinant of Health.

Beletsky L, Cochrane J, Sawyer AL, Serio-Chapman C, Smelyanskaya M, Han J, Robinowitz N, Sherman SG.

Am J Public Health. 2015 Sep;105(9):1872-9. doi: 10.2105/AJPH.2015.302681. Epub 2015 Jul 16.

12.

The role of social networks and geography on risky injection behaviors of young persons who inject drugs.

Boodram B, Mackesy-Amiti ME, Latkin C.

Drug Alcohol Depend. 2015 Sep 1;154:229-35. doi: 10.1016/j.drugalcdep.2015.06.042. Epub 2015 Jul 3.

13.

Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.

Shaheen MA, Idrees M.

World J Hepatol. 2015 Mar 27;7(3):616-27. doi: 10.4254/wjh.v7.i3.616. Review.

14.

Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study.

Schulte M, Hser Y, Saxon A, Evans E, Li L, Huang D, Hillhouse M, Thomas C, Ling W.

J Community Health. 2015 Oct;40(5):940-7. doi: 10.1007/s10900-015-0016-2.

15.

Awareness of HCV infection among persons who inject drugs in San Diego, California.

Collier MG, Bhaurla SK, Cuevas-Mota J, Armenta RF, Teshale EH, Garfein RS.

Am J Public Health. 2015 Feb;105(2):302-3. doi: 10.2105/AJPH.2014.302245.

16.

Hepatitis C surveillance among youth and young adults in New York City, 2009-2013.

Prussing C, Bornschlegel K, Balter S.

J Urban Health. 2015 Apr;92(2):387-99. doi: 10.1007/s11524-014-9920-5.

17.

HIV and HCV coinfection: prevalence, associated factors and genotype characterization in the Midwest Region of Brazil.

Freitas SZ, Teles SA, Lorenzo PC, Puga MA, Tanaka TS, Thomaz DY, Martins RM, Druzian AF, Lindenberg AS, Torres MS, Pereira SA, Villar LM, Lampe E, Motta-Castro AR.

Rev Inst Med Trop Sao Paulo. 2014 Nov-Dec;56(6):517-24.

18.

Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.

Schackman BR, Leff JA, Barter DM, DiLorenzo MA, Feaster DJ, Metsch LR, Freedberg KA, Linas BP.

Addiction. 2015 Jan;110(1):129-43. doi: 10.1111/add.12754.

19.

Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics.

Zibbell JE, Hart-Malloy R, Barry J, Fan L, Flanigan C.

Am J Public Health. 2014 Nov;104(11):2226-32. doi: 10.2105/AJPH.2014.302142. Epub 2014 Sep 11.

20.

HIV-1, HBV, HCV, HTLV, HPV-16/18, and Treponema pallidum infections in a sample of Brazilian men who have sex with men.

Soares CC, Georg I, Lampe E, Lewis L, Morgado MG, Nicol AF, Pinho AA, Salles RC, Teixeira SL, Vicente AC, Viscidi RP, Gomes SA.

PLoS One. 2014 Aug 1;9(8):e102676. doi: 10.1371/journal.pone.0102676. eCollection 2014.

Supplemental Content

Support Center